RAPT Therapeutics Inc - Asset Resilience Ratio
RAPT Therapeutics Inc (RAPT) has an Asset Resilience Ratio of 72.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read RAPT current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how RAPT Therapeutics Inc's Asset Resilience Ratio has changed over time. See RAPT Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down RAPT Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RAPT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $119.41 Million | 72.05% |
| Total Liquid Assets | $119.41 Million | 72.05% |
Asset Resilience Insights
- Very High Liquidity: RAPT Therapeutics Inc maintains exceptional liquid asset reserves at 72.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
RAPT Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare RAPT Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for RAPT Therapeutics Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for RAPT Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.52% | $61.32 Million | $240.32 Million | -38.75pp |
| 2023-12-31 | 64.26% | $111.38 Million | $173.33 Million | -14.67pp |
| 2022-12-31 | 78.93% | $210.12 Million | $266.21 Million | -4.45pp |
| 2021-12-31 | 83.38% | $165.63 Million | $198.64 Million | +10.60pp |
| 2020-12-31 | 72.79% | $86.59 Million | $118.97 Million | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more